Global /United States /Healthcare /Medical Devices /PLSE

Pulse Biosciences, Inc.

PLSE

• NASDAQ: PLSE • Delayed

20.24USD -7.3%

As of 15 June 2026, Pulse Biosciences, Inc. has a market cap of $1.38B USD, ranking #8929 globally and #1950 in the United States. It ranks #754 in the Healthcare sector, and #150 in the Medical Devices industry.

Global Rank

8929

Country Rank

1950

Sector Rank

754

Industry Rank

150

Key Stats

Market Cap

$1.38BUSD

Enterprise Value

$1.3BUSD

Revenue (TTM)

$350.0KUSD

EBITDA (TTM)

-$75.87MUSD

Net Income (TTM)

-$72.78MUSD

PS Ratio

3929.8

PB Ratio

17.0

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Medical Devices

CEO

Paul LaViolette open_in_new

Employees

116

Founded

2014

IPO

18 May 2016

Website

pulsebiosciences.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-7.3%	-17%	-1.6%	49%	17%	47%	13%	214%	-2.7%

News

PLSE Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	PLSE Pulse Biosciences Inc ISIN: US74587B1017 Shares Out.: Shares Outstanding: 69.21M¹ Shares Float: 18.477M² TV: TradingView: NASDAQ: PLSE SA: Stock Analysis: NASDAQ: PLSE YF: Yahoo Finance: PLSE GF: Google Finance: NASDAQ: PLSE NQ: NASDAQ: PLSE BA: Barron's: PLSE MS: Morningstar: XNAS: PLSE	20.24 USD	TV: TradingView: NASDAQ: PLSE SA: Stock Analysis: NASDAQ: PLSE YF: Yahoo Finance: PLSE GF: Google Finance: NASDAQ: PLSE NQ: NASDAQ: PLSE BA: Barron's: PLSE MS: Morningstar: XNAS: PLSE

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Pulse Biosciences, Inc.

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

Similar Companies

Industry: Medical Devices (United States)

Name	Market Cap (USD) diff.	PE	Country
Thermo Fisher Scientific Inc. NYSE: TMO	$173.27B 12K%	25.8	United States
Intuitive Surgical, Inc. NASDAQ: ISRG	$160.73B 12K%	56.7	United States
Abbott Laboratories NYSE: ABT	$159.07B 11K%	25.6	United States
Danaher Corp. NYSE: DHR	$126.55B 9K%	34.7	United States
Stryker Corp. NYSE: SYK	$120.69B 9K%	38.3	United States
Boston Scientific Corp. NYSE: BSX	$84.93B 6K%	24.5	United States

Industry: Medical Devices (Global)

Name	Market Cap (USD) diff.	PE	Country
Medtronic plc NYSE: MDT	$101.9B 7K%	22.2	Ireland
EssilorLuxottica Société anonyme EPA: EL	$97.46B 84.32B EUR 7K%	36.7	France
HOYA Corp. TSE: 7741	$61.41B 9.83T JPY 4K%	40.0	Japan
Siemens Healthineers AG XETRA: SHL	$45.47B 39.34B EUR 3K%	18.7	Germany
Alcon Inc. SIX: ALC	$36.38B 28.99B CHF 3K%	37.9	Switzerland
Shenzhen Mindray Bio-Medical Electronics Co., Ltd. SHE: 300760	$30.06B 203.66B CNY 2K%	26.0	China

chevron_leftBack